Antihypertensive Drugs Market Size, Share, and Trends 2024 to 2033

Antihypertensive Drugs Market (By Drug Class: Diuretics, ACE Inhibitors, Calcium Channel Blockers, Beta-adrenergic Blockers, Vasodilators, Others; By Type: Primary Hypertension, Secondary Hypertension; By Route of Administration: Oral, Injectables, Others; By Distribution Channel: Retail Pharmacy, Hospital Pharmacy, Online Pharmacy) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033

  • Last Updated : June 2024
  • Report Code : 4542
  • Category : Healthcare

Antihypertensive Drugs Market Size and Forecast

The global antihypertensive drugs market size was USD 23.61 billion in 2023, calculated at USD 24.54 billion in 2024 and is expected to reach around USD 34.71 billion by 2033, expanding at a CAGR of 3.93% from 2024 to 2033. The benefits of antihypertensive drugs include controlling hypertension by increasing urine production or blocking the RAAS system, helping the heart pump blood more effectively, reducing blood pressure by allowing blood to flow more easily and relaxing blood vessels, and helping to prevent problems like chronic kidney diseases, loss of eyesight, stroke, and heart diseases which helps to the growth of the market.

Antihypertensive Drugs Market Size 2024 to 2033

To Access our Exclusive Data Intelligence Tool with 15000+ Database, Visit: Precedence Statistics

Antihypertensive Drugs Market Key Takeaways

  • The North America antihypertensive drugs market size reached USD 8.97 billion in 2023 and is expected to attain around USD 13.36 billion by 2033, poised to grow at a CAGR of 4.06% between 2024 and 2033.
  • North America dominated the market with the largest revenue share of 38% in 2023.
  • By drug class, the calcium channel blockers (CCB) segment has contributed more than 27% of revenue share in 2023.
  • By drug class, the ACE inhibitors segment is expected to grow at a CAGR of 4.99% during the forecast period.
  • By type, the primary hypertension segment has recorded the biggest revenue share of 72% in 2023.
  • By type, the secondary hypertension segment is expected to expand at a CAGR of 4.35% during the forecast period.
  • By route of administration, the oral segment has generated the largest revenue share of 76% in 2023.
  • By route of administration, the injectables segment held the second-largest share of the market in 2023.
  • By distribution channel, the hospital pharmacy segment has held a major revenue share of 54% in 2023.
  • By distribution channel, the online pharmacy segment is expected to be the fastest-growing during the forecast period.

U.S. Antihypertensive Drugs Market Size and Growth 2024 to 2033

The U.S. antihypertensive drugs market size was exhibited at USD 6.28 billion in 2023 and is projected to be worth around USD 9.42 billion by 2033, poised to grow at a CAGR of 4.13% from 2024 to 2033.

U.S. Antihypertensive Drugs Market Size 2024 to 2033

North America dominated the antihypertensive drugs market in 2023. In North America, most of the population suffers from hypertension and needs antihypertensive drugs. In the United States and Canada, ACE inhibitors, beta-blockers, diuretics, and calcium channel blockers are the popular medications for high blood pressure. These factors help the growth of the market in the North American region.

Antihypertensive Drugs Market Share, By Region, 2023 (%)
  • In September 2023, for the treatment of hypertension or high blood pressure, a new generic drug, pms-PERINDROPIL-INDAPAMIDE, was launched by Pharmascience Inc. in Canada.
  • In January 2024, in America, Lupin received approval from the United States Food and Drug Administration (USFDA) health regulator to market a generic hypertension drug, Propranolol Hydrochloride extended-release capsule in numerous strengths.

Market Overview

The antihypertensive drugs market covers different types of antihypertensive drugs like thiazide diuretics, beta-blockers, angiotensin II receptor antagonists (ARBs), ACE inhibitors, and calcium channel blockers (CCB). Antihypertensive drugs are a class of drugs used to treat hypertension or high blood pressure, like myocardial infarction and strokes. The benefits of antihypertensive drugs include controlling hypertension by increasing urine production or blocking the RAAS system, helping the heart pump more efficiently, reducing blood pressure by allowing blood to flow more easily, and relaxing blood vessels. Antihypertensive drugs help to prevent problems like chronic kidney disease, loss of eyesight, stroke, and heart disease.

Antihypertensive Drugs Market Growth Factors

  • The benefits of antihypertensive drugs include controlling hypertension by increasing urine production or blocking the RAAS system. It helps the heart pump blood more efficiently.
  • Antihypertensive drugs help to reduce blood pressure by allowing blood to flow more easily and relaxing blood vessels.
  • It also helps to prevent problems like chronic kidney disease, high blood pressure, loss of eyesight, stroke, and heart disease. These benefits help to the growth of the antihypertensive drugs market.

Antihypertensive Drugs Market Scope

Report Coverage Details
Market Size by 2033 USD 34.71 Billion
Market Size in 2023 USD 23.61 Billion
Market Size in 2024 USD 24.54 Billion
Market Growth Rate from 2024 to 2033 CAGR of 3.93%
Largest Market North America
Base Year 2023
Forecast Period 2024 to 2033
Segments Covered Drug Class, Type, Route of Administration, Distribution Channel, and Regions
Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

 

Antihypertensive Drugs Market Dynamics

Drivers

Increasing senior population

Hypertension management is difficult in older adults, especially in the increasing senior population. In the first-line treatment, antihypertensive drugs like thiazide diuretics, angiotensin II Type 1 receptor antagonists, ACE inhibitors, calcium channel antagonists, and diuretics are preferred for older patients. The antihypertensive drugs effectively reduce blood pressure. Older adults or the senior population are a heterogeneous group, and there is a need for individualized treatment. Adjustments for antihypertensive therapy and careful monitoring are significant for effective management. Antihypertensive drugs are effective in lowering blood pressure both in SBP and DBP in the senior population. These factors help to the growth of the antihypertensive drugs market.

Rising prevalence of hypertension

The rising prevalence of hypertension leads to the growth of the market. There are many factors that lead to an increase in hypertension, including too little physical activity, too much stress, too much alcohol, too little potassium, and too much salt. Thyroid disease, obstructive sleep apnea, kidney disease, illegal drugs like amphetamines and cocaine, heart problems affecting blood vessels present at birth, and adrenal gland disorders can cause hypertension, which needs antihypertensive drugs. Some medications include prescription drugs, drug relievers containing caffeine, cold and sinus medicines, and birth control pills that may cause hypertension. These factors help to the growth of the antihypertensive drugs market.

Restraint

Disadvantages of antihypertensive drugs

The disadvantages of antihypertensive drugs include these drugs can make older adults get dizzy and fall and sometimes get injured. Some antihypertensive drugs can change electrolyte levels by losing extra fluid in urine. Too low and too high levels of potassium may cause dangerous heart rhythms. Some side effects of antihypertensive drugs include heart palpitations, constipation, cold hands and pits, fatigue, swelling in the throat or under the skin, nasal congestion, dry mouth, depression, insomnia, high blood sugar, gout, impotence, loss of taste, headaches, extreme dizziness or tiredness, headaches, too much potassium in the blood, and dry cough. These factors can restrict the growth of the antihypertensive drugs market.

Opportunity

Research & development

There is an opportunity for research & development of antihypertensive drugs. There is an opportunity for pharmaceutical companies to develop effective and innovative antihypertensive drugs. There is an opportunity for collaboration to improve patient outcomes and hypertension management with healthcare providers. The implementation of FDA regulations on these drugs. There is an opportunity for each phase of drug discovery and the development of new antihypertensive agents. These factors help to the growth of the antihypertensive drugs market.

Drug Class Insights

The calcium channel blockers (CCB) segment dominated the antihypertensive drugs market in 2023. Calcium channel blockers are a type of drug used to treat high blood pressure. Some examples of calcium channel blockers (CCB) include verapamil, nisoldipine, nicardipine, isradipine, felodipine, diltiazem, amlodipine, etc. The benefits of calcium channel blockers include controlling irregular heartbeats, lowering blood pressure, relaxing blood vessels, reducing the risk of cardiovascular events like strokes and heart attacks, working alongside other medications, targeting specific conditions, being a better option in some cases, and effectiveness in the treatment of circulatory and heart problems. These factors help the growth of the calcium channel blockers drug type segment and contribute to the growth of the market.

The ACE inhibitors segment is estimated to be the fastest-growing during the forecast period. ACE inhibitors drugs are angiotensin-converting-enzyme inhibitors. ACE inhibitors are the type of drugs that help to open and relax blood vessels and have benefits for many conditions. The benefits of ACE inhibitors are treating migraines and scleroderma, reducing the risks of type 2 diabetes, stroke, and mortality from cardiovascular causes, slowing or preventing the progression of kidney failure, especially in people with chronic kidney diseases or diabetes, and preventing, treating, and improving symptoms of coronary artery diseases, heart failure, high blood pressure, and heart attacks. ACE inhibitors also help to improve blood flow and lower blood flow. These factors help the growth of the ACE inhibitors drug class type segment and contribute to the growth of the antihypertensive drugs market.

Type Insights

The primary hypertension segment dominated the antihypertensive drugs market in 2023. In most of the adults, there is no identifiable cause of high blood pressure. This type of high blood pressure is called essential hypertension or primary hypertension. The causes of primary hypertension are genetics, lifestyle, and age factors that contribute to the primary hypertension. Lifestyle factors include unhealthy habits like alcohol use disorders, sleep issues like insomnia, a sedentary lifestyle in that lack of physical activity, being overweight, excessive coffee or caffeine intake, and a diet that consumes too much salt. Symptoms of primary hypertension include blood vessel damage, which leads to severe headaches, nosebleeds, fatigue, dizziness, shortness of breath, chest pain, and blurred vision.

To treat this primary hypertension, there is a need for antihypertensive drugs. There are complications of primary hypertension that may damage blood vessels and lead to serious health issues, including vision loss, stroke, malignant hypertension, kidney disease, heart failure, heart attack, dementia, and brain aneurysm. These factors help to the growth of the primary hypertension segment and contribute to the growth of the market.

The secondary hypertension segment is estimated to grow significantly during the forecast period. The causes of secondary hypertension include constriction of the aorta, thyroid abnormalities, hormone abnormalities, obstructive sleep apnea, adrenal gland disease, and narrowing of arteries that supply blood to the kidneys. Side effects of some medications include over-the-counter medications, antidepressants, stimulants, diet aids, and birth control pills, which lead to secondary hypertension. To overcome this secondary hypertension, there is a need for antihypertensive drugs. These factors help the growth of the secondary hypertension type segment and contribute to the growth of the antihypertensive drugs market.

Route of Administration Insights

The oral segment dominated the antihypertensive drugs market in 2023 and is expected to be the fastest growing during the forecast period. It is the safest, most convenient, and simplest type of antihypertensive drug administration. It is convenient for prolonged and repeated use and can be pain-free and self-administered. Oral types of antihypertensive drugs include diuretic water pills that help to reduce excessive water and salt from the body and reduce blood pressure and volume, beta-blockers that help to lower heart rate, which reduces blood pressure, ACE inhibitors that help to widen blood vessels to make easy blood flow and help to reduce blood pressure, angiotensin II receptor blockers relax blood vessel that helps to lower blood pressure, and calcium channel blockers help to reduce the amount of calcium entering in heart muscles that leads to decrease in blood pressure and heart rate. These factors help to grow the oral route of the administration-type segment and contribute to the growth of the market.

The injectables segment held the second-largest share of the market in 2023. The injectable antihypertensive drug administration type includes diuretics that help to remove kidneys excess water and salt from the body, calcium channel blockers that help to reduce blood pressure, and angiotensin II receptor antagonists. Injectable drugs offer many benefits over the other routes of administration, including fast onset of action, predictable bioavailability, and precise and adjustable dosing. These factors help to the growth of the injectable route of the administration and contribute to the growth of the antihypertensive drugs market.

Distribution Channel Type Insights

The hospital pharmacy distribution channel segment dominated the antihypertensive drugs market in 2023. Hospital pharmacy benefits include effective and safe medication therapy for hospitalized patients and support for other healthcare services and activities. It also includes reduced medication discrepancy and improved medication use, potential hospital revenue, care team collaboration, and improved patient satisfaction. These factors help the growth of the hospital pharmacy distribution channel type segment and contribute to the growth of the market.

Antihypertensive Drugs Market Share, By Distribution Channel, 2023 (%)

The online pharmacy segment is expected to be the fastest-growing during the forecast period. The benefits of online pharmacies include fast and secure shipping, help to save money, provide virtual advice, offer a wide range of products, help to save time as compared to traditional pharmacies, and offer convenient and practical shopping methods. These factors help the growth of the online pharmacy distribution channel type segment and contribute to the growth of the antihypertensive drugs market.

Antihypertensive Drugs Companies

Antihypertensive Drugs Market Companies

  • Sun Pharmaceutical Industries Ltd.
  • Lupin
  • Pfizer Inc.
  • AstraZeneca
  • Merck & Co., Inc.
  • DAIICHI SANKYO COMPANY, LIMITED
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Boehringer Ingelheim International GmbH
  • Sanofi
  • Medtronic Plc.

Recent Developments

  • In November 2023, a global leader in healthcare technology, Medtronic Plc., announced that the USFDA (United States Food and Drug Administration) has approved the Simplicity blood pressure procedure, also known as Simplicity Spyral renal denervation (RDN) system for hypertension or high blood pressure treatment.
  • In December 2023, Innovent Biologics, Inc. and Sanegene Bio USA Inc. entered into a strategic collaboration to develop siRNA drugs for hypertension or high blood pressure treatment.

Segments Covered in the Report

By Drug Class

  • Diuretics
  • ACE Inhibitors
  • Calcium Channel Blockers
  • Beta-adrenergic Blockers
  • Vasodilators
  • Others

By Type

  • Primary Hypertension
  • Secondary Hypertension

By Route of Administration

  • Oral
  • Injectables
  • Others

By Distribution Channel

  • Retail Pharmacy
  • Hospital Pharmacy
  • Online Pharmacy

By Geography

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • Middle East & Africa

Frequently Asked Questions

The global antihypertensive drugs market size is expected to increase USD 34.71 billion by 2033 from USD 23.61 billion in 2023.

The antihypertensive drugs market is anticipated to grow at a CAGR of over 3.93% between 2024 and 2033

The major players operating in the antihypertensive drugs market are Sun Pharmaceutical Industries Ltd., Lupin, Pfizer Inc., AstraZeneca, Merck & Co., Inc., DAIICHI SANKYO COMPANY, LIMITED, Johnson & Johnson Services, Inc., Novartis AG, Boehringer Ingelheim International GmbH, Sanofi, Medtronic Plc., and Others.

The driving factors of the antihypertensive drugs market are the increasing senior population and rising prevalence of hypertension.

North America region will lead the global antihypertensive drugs market during the forecast period 2024 to 2033.

Proceed To Buy

USD 5400
USD 3800
USD 2100
USD 2100
USD 7500

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client